Potential Treatment For Advanced Post-Menopausal Breast Cancer Patients Resistant To
 

Results from a phase III clinical trial have shown that combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy significantly improves outcome...

More...

Re: Potential Treatment For Advanced Post-Menopausal Breast Cancer Patients Resistant
 

Great news,

let's hope everolimus/afinitor gains approval from the FDA as soon as possible.

I'm also looking forward to see the results of the others two phase III trials, bolero 1 and bolero 3, which are looking at the combination of everolimus and herceptin for metastatic her2 pos breast cancer.

I was wondering, if the drug get the approval for estrogen receptor positive BC, this is limited to ER+/Her2- or it includes ER+/Her+ as well?